Anders Olsen and colleagues explore patenting on insulin products by the Federal Drug Agency (FDA) and the impact on market exclusivity and drug prices.

Related Keywords

Australia , United States , Canada , Japan , Eli Lilly , Mylan Semglee , Lilly Humalog , Sanofi Lantus , Lilly Basaglar , Sanofi Admelog , Lilly Rezvoglar , National Heart , Drug Administration , European Patent Office , Trademark Office , Us Court , Virginia University Hodges Research Grant , World Health Organization , Alosa Health , Obrien Institute Of Public Health , European Union , Microsoft , Commonwealth Fund , Rr Core Team , Blood Institute , Novo Nordisk , Office Of The , National Bureau For Economic Research , Napproved Drug Products , Therapeutic Equivalence Evaluations , Orange Book , New Drug Application , Google Patents , Cosmetic Act , Creative Commons Attribution License , Drug Products , Arnold Ventures , O Brien Institute , Public Health , West Virginia University , Hodges Research Grant , Assistant Secretary , Editorial Board , National Bureau , Economic Research , Therapeutics Equivalence Evaluations , Orange Books , Review Board , Inflation Reduction Act , First Circuit , Federal Trade Commission , Abbreviated New Drug Applications , Biologics Licensing Applications , Purple Book , Insulin , Drug Prices , Drug Regulation , Diabetes Mellitus , Patents , Drug Discovery , Patients ,